ADAR1 Capital Management, the largest stockholder of Keros Therapeutics with 13.3% ownership, has announced that Institutional Shareholder Services (ISS), a leading proxy advisory firm, recommends stockholders withhold votes from directors Dr. Mary Ann Gray and Dr. Alpna Seth at Keros's upcoming Annual Meeting on June 4, 2025. ISS expressed concerns over the company's governance, highlighting the need for greater accountability. ADAR1 supports this recommendation, emphasizing the benefits of fresh, independent directors. Additionally, ADAR1 urges Keros to disclose the results of its strategic review before the meeting, as stockholders are required to vote without knowing the outcomes of the Board's strategic process.